These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4186794)

  • 41. Primary dysmenorrhea: combination vs sequential therapy.
    Buttram VC; Kaufman RH
    Tex Med; 1969 Aug; 65(8):52-5. PubMed ID: 4185963
    [No Abstract]   [Full Text] [Related]  

  • 42. [Estro-progestogenic therapy of the "menopausal syndrome", using a sequential technic].
    Zinelli G; Spreafichi F
    Ann Ostet Ginecol Med Perinat; 1968 Dec; 90(12):873-95. PubMed ID: 4183087
    [No Abstract]   [Full Text] [Related]  

  • 43. Oral menopausal therapy using 17- micronized estradiol. A preliminary study of effectiveness, tolerance and patient preference.
    Martin PL; Burnier AM; Greaney MO
    Obstet Gynecol; 1972 May; 39(5):771-4. PubMed ID: 5023261
    [No Abstract]   [Full Text] [Related]  

  • 44. Significance of dysmenorrhea in infertility. Report of a preliminary study of therapy with a sequential estrogen-progestagen regimen.
    Roland M; Clyman M; Decker A; Ober WB
    Pac Med Surg; 1966; 74(3):135-8. PubMed ID: 4160710
    [No Abstract]   [Full Text] [Related]  

  • 45. Graded sequential therapy in the menopause: a double-blind study.
    Martin PL; Burnier AM; Segre EJ; Huix FJ
    Am J Obstet Gynecol; 1971 Sep; 111(2):178-86. PubMed ID: 4938602
    [No Abstract]   [Full Text] [Related]  

  • 46. Development of a new sensitive and specific time-resolved fluoroimmunoassay (TR-FIA) of chlormadinone acetate in the serum of treated menopausal women.
    Fiet J; Giton F; Auzerie J; Galons H
    Steroids; 2002 Dec; 67(13-14):1045-55. PubMed ID: 12441190
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Physiological effects of estrogens on ovarian function. Personal study of the suppression of ovulation by "diphasic" therapy. Applications in pathology].
    Netter A; Pelissier C
    Presse Med (1893); 1966 Apr; 74(22):1129-30. PubMed ID: 4160054
    [No Abstract]   [Full Text] [Related]  

  • 48. [Changes in the serum triglyceride levels following treatment with ovulation inhibitors in tall girls].
    Schambach H; Köhler P
    Z Gesamte Inn Med; 1980 Mar; 35(5):232-4. PubMed ID: 6157258
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Estrogens. Replacement therapy. Mestranol 80 ug (1962) versus mestranol 20 ug (1994) in postmenopausal women. Clinical, local, and metabolic effects].
    Cortés Gallegos V; Sojo Aranda I
    Ginecol Obstet Mex; 1995 Jan; 63():55-8. PubMed ID: 7896161
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The use of selected cytologic indices for evaluation of estrogenicity of synthetic compounds.
    Teter J
    Acta Cytol; 1972; 16(4):366-75. PubMed ID: 4556412
    [No Abstract]   [Full Text] [Related]  

  • 52. [Clinical experiences with two sequential oral contraceptive agents].
    Larsson-Cohn U
    Lakartidningen; 1968 Dec; 65(51):5115-20 passim. PubMed ID: 4192633
    [No Abstract]   [Full Text] [Related]  

  • 53. [Clinical experience with hormonal suppression of ovulation using the sequential method with chlormadinone acetate and mestranol in different dosage].
    Heinen G
    Med Welt; 1969 Nov; 44():2420-6. PubMed ID: 5374595
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Gas chromatography of oral progestagens and estrogens.
    Prous JR; Sussmann AR
    Med Actual; 1968; 4(2):56-7. PubMed ID: 12334354
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [The cytohormonal diagnosis under various oral contraceptives].
    Loch EG; Tenhaeff D; Lohmeyer H
    Z Geburtshilfe Gynakol; 1970; 172(3):261-6. PubMed ID: 12156325
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Evaluation of norethindrone combined with mestranol (S-3800 C) as an oral contraceptive].
    Seiga K
    Iryo; 1968 Apr; 22(4):444-52. PubMed ID: 5686370
    [No Abstract]   [Full Text] [Related]  

  • 57. [Experimental treatment of menopausal disorders by an estrogen-progestogen combination with the estrogen dominant or mixed and then a weak estrogen-progestogen combination].
    Dorangeon P
    Rev Fr Gynecol Obstet; 1974 Jan; 69(1):49-54. PubMed ID: 17436492
    [No Abstract]   [Full Text] [Related]  

  • 58. [Pharmacological inhibition of ovulation].
    Haller J
    Fortschr Geburtshilfe Gynakol (1950); 1965; 21():37-106. PubMed ID: 12255694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The menopause--its meaning and management.
    Marino ER
    Trans N Engl Obstet Gynecol Soc; 1964; 18():119-23. PubMed ID: 5832964
    [No Abstract]   [Full Text] [Related]  

  • 60. Thromboembolic disease and the steroidal content of oral contraceptives.
    Swyer GI
    Res Reprod; 1970 Jul; 2(4):1. PubMed ID: 12254979
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.